CDT Equity Inc. (NASDAQ:CDT) Stock Short Interest Report for September

CDT Equity Inc. (NASDAQ:CDT) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 38,202 shares, a drop of 84.1% from the September 15th total of 239,903 shares. Based on an average daily volume of 503,746 shares, the days-to-cover ratio is presently 0.1 days. Approximately 131.7% of the company’s shares are sold short.

CDT Equity Trading Down 8.1%

NASDAQ CDT traded down $0.06 during trading hours on Monday, hitting $0.66. 339,595 shares of the company’s stock were exchanged, compared to its average volume of 75,120. The stock has a 50-day simple moving average of $32.90 and a 200 day simple moving average of $352.75. CDT Equity has a 1-year low of $0.63 and a 1-year high of $28,125.00. The firm has a market cap of $19,800.00, a price-to-earnings ratio of -0.00 and a beta of 1.59.

CDT Equity (NASDAQ:CDT) last issued its earnings results on Wednesday, August 12th. The company reported ($217.75) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on CDT shares. Wall Street Zen raised shares of CDT Equity from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has an average rating of “Sell”.

About CDT Equity

CDT Equity, Inc, operating under the Conduit Pharmaceuticals name, is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and fibrotic diseases. The company seeks to advance medicines for conditions with significant unmet medical needs by acquiring or licensing promising clinical-stage drug candidates from pharmaceutical companies, universities and research institutions.

Conduit’s development strategy is centered on progressing externally sourced assets through clinical development and, where appropriate, partnering with larger pharmaceutical companies for commercialization.